Simplex Trading
XBIO icon

Simplex Trading’s Xenetic Biosciences XBIO Stock Holding History

Simplex Trading’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-136
Closed – – 10093
2023
Q1 		$0 Buy
+136
New +$660 ﹤0.01% 10283
2022
Q2 		– Sell
-1,429
Closed -$11.6K – 11259
2022
Q1 		$14K Sell
1,429
-2,986
-68% -$31.2K ﹤0.01% 8621
2021
Q4 		$56K Buy
+4,415
New +$70.4K ﹤0.01% 7113

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Simplex Trading's XBIO Position: Q2 2023 in Review

Simplex Trading sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 136 shares.

Simplex Trading first reported a position in XBIO in Q4 2021 and held it in 3 quarters. The position peaked at $56K in Q4 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

  • Simplex Trading reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 136 Xenetic Biosciences shares in Q2 2023.
  • Simplex Trading first reported a position in Xenetic Biosciences in Q4 2021 and held it in 3 quarters.
  • Simplex Trading's Xenetic Biosciences position peaked at $56K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.